1 unknown. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
Follow SENAI CIMATEC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Safety, Reactogenicity and Immunogenicity of the VACCINE RNA MCTI CIMATEC HDT (HDT-301) Vaccine Against COVID-19 Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine, Cohort 2 RNA VACCINE MCTI CIMATEC HDT(HDT-301) vaccine, Cohort 3 VACCINE RNA MCTI CIMATEC HDT(HDT-301) vaccine - SARS-CoV-2 | Phase 1 | Unknown | SENAI CIMATEC | 90 | 2022-01-13 | 2022-04-04 |
Vaccines (1) · repRNA-CoV2S vaccine (1)
Brazil (1)
Steven Reed, PhD (1)